Quick Answer
Oruka Therapeutics, Inc. reported Total Assets of $488.62 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed an increase of +23.4% in Total Assets from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $8.58 million | Q3 2011: $6.50 million | Q1 2012: $4.96 million | Q2 2012: $3.82 million | Q3 2012: $3.46 million | Q1 2013: $4.14 million | Q2 2013: $20.78 million | Q3 2013: $19.14 million | Q1 2014: $22.66 million | Q2 2014: $20.54 million | Q3 2014: $18.04 million | Q1 2015: $13.26 million | Q2 2015: $45.12 million | Q3 2015: $42.40 million | Q1 2016: $36.93 million | Q2 2016: $32.64 million | Q3 2016: $28.68 million | Q1 2017: $20.59 million | Q2 2017: $17.30 million | Q3 2017: $16.92 million | Q1 2018: $12.79 million | Q2 2018: $10.07 million | Q3 2018: $8.45 million | Q1 2019: $8.61 million | Q2 2019: $10.39 million | Q3 2019: $9.95 million | Q1 2020: $7.46 million | Q2 2020: $11.63 million | Q3 2020: $51.98 million | Q1 2021: $69.18 million | Q2 2021: $65.34 million | Q3 2021: $60.19 million | Q1 2022: $51.01 million | Q2 2022: $48.10 million | Q3 2022: $44.97 million | Q1 2023: $42.06 million | Q2 2023: $41.08 million | Q3 2023: $39.18 million | Q4 2023: $37.86 million | Q1 2024: $36.71 million | Q2 2024: $33.84 million | Q3 2024: $414.09 million | Q1 2025: $377.11 million | Q2 2025: $357.42 million | Q3 2025: $509.25 million.
- Over the full 17 years of available data (2010 to 2025), Oruka Therapeutics, Inc.'s Total Assets has grown by 5,890.9%.
- Historical annual values: Fiscal year 2025: $488.62 million | Fiscal year 2024: $396.02 million | Fiscal year 2024: $1.0 thousand | Fiscal year 2023: $37.86 million | Fiscal year 2022: $43.09 million | Fiscal year 2021: $54.92 million | Fiscal year 2020: $50.43 million | Fiscal year 2019: $8.54 million | Fiscal year 2018: $6.83 million | Fiscal year 2017: $12.37 million | Fiscal year 2016: $24.63 million | Fiscal year 2015: $39.57 million | Fiscal year 2014: $16.13 million | Fiscal year 2013: $17.08 million | Fiscal year 2012: $3.21 million | Fiscal year 2011: $6.50 million | Fiscal year 2010: $8.16 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: